The backlog inflected. The earnings quality did not—yet.

What is recurring

• Q4 non-GAAP gross margin reached 44.7%, up from 34.4% in Q3, as revenue and mix improved. S1
• Non-GAAP operating income was $0.955 million, a 5.1% margin; non-GAAP pre-tax income was $1.706 million. S1
• Backlog expansion and product mix—not a broad revenue beat—are the durable positives.
• Derived Q4 free cash flow was about $1.7 million, but the full-year figure was negative $5.4 million. S1

What is not yet clean

• The $1.846 million tax benefit equaled 133% of GAAP net income and about 52% of non-GAAP net income.
• The tax benefit contributed roughly $0.056 per diluted share; non-GAAP pre-tax income equaled only about $0.051 per share before a normalized tax rate.
• For FY2026, non-GAAP pre-tax loss was $3.700 million, while a $4.610 million tax benefit produced $0.910 million of non-GAAP net income. S1
• Cash rose mostly because Aehr raised $97.4 million net through equity offerings, not because the business generated cash. S1S5

Demand evidence

Q4 bookings were $60.7 million, following $37.2 million in Q3. Effective backlog almost doubled sequentially to $100.6 million; reported backlog rose 108% to $80.6 million. S1S2

Coverage math

Effective backlog covers 67%–77% of the $130–150 million revenue guide and 72% of its midpoint. That is unusually strong visibility, but it is not the same as recognized revenue: delivery, customer acceptance and cancellation terms still matter.

Cadence

Management described a solid Q1, a very strong Q2, roughly flat Q3 and higher Q4; first-half revenue could equal or exceed second-half revenue. Roughly $50 million of Sonoma package-level revenue and 60–70 systems are concentrated around Q2. S3

Fallback: revenue rose from $10.3m in Q3 to $18.8m in Q4; GAAP gross margin rose from 32.7% to 42.6%; GAAP operating margin improved from –41.0% to –6.4%.

Fallback: adjusted EPS actuals were –$0.01, $0.01, –$0.04, –$0.05 and $0.11. The latest consensus was roughly –$0.01.

Fallback: AEHR closed at $72.01 before the print, $87.79 the next day, and traded at $77.17 at Jul 20, 2026, 2:09 PM ET. The first-day peak was $110.20.

Reaction scorecard

The market initially repriced the record backlog and FY2027 scale, with first-day volume roughly 4.9× the 20-day average. By the intraday snapshot, the stock had given back most of the peak response. A sizable short base—4.16 million shares at June 30, roughly 14% of float by secondary-source denominators—likely amplified the first move, but does not explain the fundamental re-rating by itself. S7S8

Fallback: FY2027 revenue consensus rose from $86.85m to $136.27m; adjusted EPS rose from $0.15 to $0.75.

Estimate reset versus official range

• FY2027 revenue mean: $136.3 million, inside the official $130–150 million range and 2.7% below midpoint. S6
• FY2027 adjusted EPS mean: $0.75, based on three contributors; basis comparability with the company’s percentage guide is not fully reconciled.
• FY2028 mean: $201.8 million revenue and $1.38 adjusted EPS, already assuming another year of strong scaling. S6
• Published post-print targets: $110–$125, $115 mean, with four Buy ratings shown by the vendor. Individual estimate timestamps were not supplied in the local feed. S6

Advanced packaging raises the value of early screening

As accelerator packages become more expensive and complex, detecting failures before final assembly improves the economics of wafer-level burn-in. This supports Aehr’s core thesis without identifying any unnamed customer.

Optical interconnect is becoming a second AI leg

Follow-on FOX-XP orders and a newer customer’s multi-wafer cells show photonics moving from evaluation into production. Broader 400G/lane and 1.6T industry roadmaps support the demand backdrop. S10S11

Hyperscalers validate demand but do not guarantee supplier standardization

AI customers are requiring more rigorous screening, yet management said hyperscalers are not broadly directing semiconductor vendors to Aehr. Automotive OEM pull-through appears stronger today.

The same AI boom pressures inputs

Demand from large compute programs validates the test market, but it also competes for Aehr’s power-supply inputs. A 40% quoted increase is a concrete margin and schedule watchpoint. S3

What the stock appears to discount

Near 17× guide-midpoint sales and more than 100× FY2027 consensus EPS, the stock already assumes successful backlog conversion, major operating leverage and continued FY2028 growth. Merely hitting FY2027 guidance may validate the business without expanding the multiple.

What can still create upside

A production order from the benchmark customer, a wafer-level win on the third hyperscaler device, durable photonics follow-ons or a sponsored memory program could push revenue above the base range and extend the runway. Each requires a purchase order or production milestone—not just evaluation progress.

What proves the thesis

• Q1/Q2 conversion: Sonoma and FOX deliveries land within the described cadence, without acceptance slippage.
• Recurring margin: non-GAAP operating and pre-tax margin scale toward the guide, independent of tax benefits.
• Customer expansion: the newly benchmarked AI supplier places a pilot or production order.
• Diversification: photonics follow-on systems and SiC orders broaden backlog beyond the two AI customers.
• Cash discipline: working-capital needs rise more slowly than revenue and dilution stabilizes.

What breaks the thesis

• Timing: the Q2 system wave moves out, exposing the concentration embedded in the guide.
• Economics: power-supply inflation, hiring or expedited components prevent gross-margin scale.
• Demand quality: bookings normalize before backlog converts or the benchmark customer remains pilot-only.
• Concentration: any of the three >10% Q4 customers slows; two were AI and one optical. S3
• Capital quality: further equity issuance offsets the per-share benefit of earnings growth.

Catalyst timeline

Capital and governance watch

Aehr ended Q4 with $116.4 million cash and no funded debt, providing ample working capital. But that strength came with dilution: shares outstanding rose 4.9% sequentially and FY2026 net offering proceeds were $97.4 million. S1S5

The company exhausted a $40 million ATM and then announced and completed a new $60 million ATM within nine days in April. That speed improved funding capacity ahead of the ramp, but per-share outcomes should be monitored separately from headline net income.